Polo-like kinases play critical roles during multiple stages of cell cycle progression. All Polo-like kinases contain an N-terminal Ser/Thr kinase catalytic domain and a Cterminal region that contains one or two Polo-boxes. For Polo-like kinase 1, 2, and 3, and their homologs, the entire C-terminal region, including both Polo-boxes, functions as a single modular phosphoserine/threonine-binding domain known as the Polo-box domain (PBD). In the absence of a bound substrate, the PBD inhibits the basal activity of the kinase domain. Phosphorylation-dependent binding of the PBD to its ligands releases the kinase domain, while simultaneously localizing Polo-like kinases to specific subcellular structures. These observations suggest two different models for how the PBD integrates signals arising from other mitotic kinases to target the activated kinase towards distinct substrates. The recent X-ray crystal structures of the PBD provide insights into the structural basis for PBD function and kinase regulation. Molecular modelling of the structure of the isolated kinase domain reveals a potential basis for motif-dependent substrate specificity.
Polo-like kinases (Plks) play key roles during multiple stages of mitosis including prophase, metaphase, anaphase, and cytokinesis, in addition to less well understood roles during G 1 /S and in response to DNA damage (Barr et al., 2004) . Originally named after the phenotype in flies, polo was found to encode a protein kinase whose mutation resulted in abnormal spindle poles (Sunkel and Glover, 1988; Llamazares et al., 1991) . Flies, budding yeast, and fission yeast contain a single Plk family member (Polo, Cdc5, and Plo1, respectively) , while humans, mice, frogs, and worms have three Plk family members, denoted Plk1/Plx1/Plc1, Plk2/Plx2/Plc2 (originally known as Snk), and Plk3/ Plx3/Plc3 (originally known as Fnk or Prk).
Plks are defined by two conserved features -an Nterminal Ser/Thr kinase domain and a C-terminal duplicated Polo-box region (Figure 1 ). The kinase domains are very highly conserved among all Plks, and most closely resemble those in Aurora kinases and calcium/calmodulin-dependent kinases. The region that encompasses the two C-terminal Polo-boxes is much less conserved, with only B70 amino acids considered to form the 'core', which constitutes less than half the full length of the C-terminal domain. This entire region has recently been renamed the Polo-box domain (PBD) due to the fact that it functions as a single unit, as described in detail below.
In humans, Plk1 is expressed primarily during late G 2 and M phases, where it appears to regulate much of the machinery involved in mitosis (Golsteyn et al., 1994; Barr et al., 2004) . Plk2 is expressed primarily in early G 1 , where it may control entry into S phase (Simmons et al., 1992; Liby et al., 2001; Ma et al., 2003) . Plk3 appears to be expressed at constant levels throughout the cell cycle, and plays a role in several stress response pathways, including those activated by DNA damage and spindle disruption (Donohue et al., 1995; Xie et al., 2001; Bahassi el et al., 2002; Xie et al., 2002) . Plk2 and Plk3 may also have overlapping roles with Plk1 in several mitotic functions, most notably Golgi fragmentation and cytokinesis (Conn et al., 2000; Wang et al., 2002; Burns et al., 2003; Ruan et al., 2004; Xie et al., 2004) . In addition, Plk2 and Plk3 have roles in remodelling postmitotic neurons (Kauselmann et al., 1999; Pak and Sheng, 2003) . Yeast and flies probably accomplish the same set of functions using only their single Plk family members, although the mitotic functions of these kinases have been most extensively studied. Similarly, there has been only limited study of worm Plks, and the data so far suggest that these genes have only limited overlapping functions with other Plk1 orthologs and paralogs (Barr et al., 2004) .
Each of the three Plks in humans, mice, and frogs appear to be orthologous between species and paralogous within a species, since phylogenetic analysis of their sequences reveals that each group clusters separately ( Figure 2a) . Thus, the expansion from one to three Plks must have been an early evolutionary event. However, this expansion appears to have occurred at least twice because the three worm Plk paralogs cluster together separately from the Plks of other organisms. This is consistent with the individual worm Plks having less functional overlap with the other Plk family members. Plk genes from organisms with single family members are slightly more evolutionarily conserved with the Plk1 class than any other, belying their conserved mitotic function. (Figure 2b) There are no identified proteins with homology to Plks in bacteria, archae, or plants. This is somewhat surprising for plants because plants have cyclin-dependent kinases and much of the same cell cycle machinery as yeast and animals. However, plants also show many novel features of cell cycle control (Dewitte and Murray, 2003) . With several plant genome sequencing projects complete or nearly complete, it seems increasingly unlikely that plant Plks are still awaiting discovery.
A fourth family member has also been characterized in humans and mice, and sequenced in frogs and flies, called Sak or Plk4. Plk4 has a highly divergent C-terminus from the other Plk family members though its kinase domain closely resembles all other Plks. At the extreme C-terminus Plk4 contains a single 'Polo-box' instead of the tandem 'Polo-box' repeats seen in all other Plks. This single 'Polo-box' is the most divergent in sequence and has been shown to mediate Sak dimerization in vitro and when overexpressed in vivo (Leung et al., 2002) . Like all other Plks, Sak has been implicated in orchestrating cytokinesis (Hudson et al., 2000; Hudson et al., 2001; Leung et al., 2002) , but its function remains largely unknown. The large (>500 amino acids) region between the kinase and the single Polo-box in Sak is a complete mystery as it has no obvious strong homology to any known proteins and no function has been assigned to it.
How Plks are regulated and how they select their substrates, many of which are unknown, to control so many distinct aspects of cell division has become the recent subject of intense investigation.
Function of the PBD
Plk activity is controlled by intracellular localization in addition to being regulated at the level of protein abundance. During prophase and metaphase, Plk1 and related family members localize to centrosomes and spindle pole bodies (Lee et al., 1998; Logarinho and Sunkel, 1998; Shirayama et al., 1998; Qian et al., 1998a; Moutinho-Santos et al., 1999; Qian et al., 1999) , where they are required for spindle assembly and centrosome maturation, presumably by phosphorylating largely unknown centrosome-associated targets (Lane and Nigg, 1996; do Carmo Avides et al., 2001) . Plk1 family members then relocalize to the spindle midzone during late anaphase (Golsteyn et al., 1994 (Golsteyn et al., , 1995 Glover et al., Figure 1 Domain structure and key residues of Plks. Plks contain an amino-terminal kinase domain and a carboxy-terminal PBD connected by a short linker. Plks are activated by phosphorylation of a conserved Thr residue within the T-loop (Thr-210), and bind phosphopeptides through a pocket in the PBD containing the key residues Trp-414, His-538, and Lys-540. Numbering is for human Plk1 Figure 2 Phylogenetic analysis of Plk family members. (a) Full-length sequences of known Plk family members were aligned using ClustalW (Thompson et al., 1994) . A rooted tree was constructed using PHYLIP (Felsenstein, 1997) showing one model of evolutionary descent. (b) An unrooted tree shows the distance relationship between Plks from organisms containing only a single Plk family member (Polo, Plo1, Cdc5) from other members of the Plk family Structure and function of Polo-like kinases DM Lowery et al 1998; Logarinho and Sunkel, 1998; Qian et al., 1999) , perhaps facilitating microtubule sliding or some aspect of kinetochore dynamics (Lee et al., 1995) , and eventually come to flank the central portion of the cytokinetic bridge (i.e. the midbody) during telophase and cytokinesis (Golsteyn et al., 1994; Lee et al., 1995; Moutinho-Santos et al., 1999; Qian et al., 1999; Song et al., 2000) . At least for Cdc5, a portion of the protein is localized at the future site of cytokinesis (the bud neck in budding yeast) from late G 2 onward (Sakchaisri et al., 2004) , indicating that Plks may be involved in organizing the structures that will eventually result in cytokinesis.
The PBD is critical for both Plk localization and function, since mutations in the conserved residues of human Plk1 result in loss of Plk1 localization to spindle poles and the bud neck, and an inability to support mitosis at the restrictive temperature in cdc5-ts complementation experiments (Lee et al., 1998) . Overexpression of the isolated PBD causes a failure to complete cytokinesis in budding yeast (Song and Lee, 2001) , and preanaphase arrest in mammalian cells (Seong et al., 2002) . The molecular basis of PBD function was clarified by the recent finding that the entire PBD, including both Polo-boxes, the region between them, and a portion of the linker between the end of the kinase domain and the first Polo-box, function as a single phosphoserine/threonine-binding module (Elia et al., 2003a) . Intriguingly, the optimal sequence motif recognized by the PBD is Ser-[pSer/ pThr]-[Pro/X], suggesting that Cdks, MAP kinases, and other mitotic kinases might generate 'priming' phosphorylations on substrates or docking proteins to localize Plks in the vicinity of their substrates. An optimal PBD-binding phosphopeptide displaces the PBD from binding to centrosomes in experiments using permeabilized cells (Elia et al., 2003a) , and mutations in the PBD that prevent phospho-peptide binding (Figure 1 ) also prevent centrosomal localization (Elia et al., 2003b) . Thus, the phosphopeptide-binding function of the PBD is intricately linked to how Plks control cell cycle progression through mitosis.
There are two alternative, although not mutually exclusive, models for how the PBD might function to direct Plk kinase activity (Figure 3 ). In one model, which we refer to as the 'processive phosphorylation' model, the PBD first binds to a site on a protein that has been previously phosphorylated by a mitotic priming kinase. This positions the kinase domain of Plk to phosphorylate the same protein at another site. This type of processive phosphorylation is seen for the Tyr kinase Src, which contains a pTyr-binding SH2 domain (Mayer et al., 1995; Pellicena et al., 1998; Scott and Miller, 2000) , and for the Ser/Thr kinase GSK-3, whose kinase domain contains a separate pSer/pThr-binding pocket in the substrate binding cleft (Frame and Cohen, 2001 (Zhou et al., 2003) , Nlp (Casenghi et al., 2003) , TCTP (Yarm, 2002) , MKlp1 (Lee et al., 1995; Liu et al., 2004) , MKlp2 (Neef et al., 2003) , Grasp65 (Lin et al., 2000; Sutterlin et al., 2001) , and Wee1 (Sakchaisri et al., 2004; Watanabe et al., 2004) . All of these contain potential PBD-binding sites, but only half match the phosphorylation motif of the only known priming kinases for PBD binding, CDK/MAPK. Also, Cdc25C, MKlp1, MKlp2, TCTP, Grasp65, and NudC have been definitively shown to interact with the Plk1-PBD (Lin et al., 2000; Sutterlin et al., 2001; Yarm, 2002; Elia et al., 2003a, b; ; Neef et al., 2003; Zhou et al., 2003; Liu et al., 2004) . (Interactions with the other substrate proteins have either not been examined or have only been assessed with full-length Plk1.) In addition, Cdc25C, Brca2, MKlp2, Grasp65, Wee1, and Myt1 are known to be phosphorylated by Cdk1; and NudC, cyclin B, and TCTP are similarly phosphorylated by mitotic kinases other than Plk1, although the identity of these kinases and the sites and timing of phosphorylation are not known. Taken together, these data suggest that the processive phosphorylation model may apply to at least some of these substrates. In vitro, however, Plk1 can phosphorylate bacterially produced (and therefore unprimed) Cdc25C (Kumagai and Dunphy, 1996) , TCTP (Yarm, 2002) , Myt1 (Nakajima et al., 2003) , cyclin B (Jackman et al., 2003) , and NudC (Zhou et al., 2003) , suggesting that priming phosphorylation is not absolutely required under conditions of high substrate and enzyme concentration. The kinetics and efficiency of phosphorylation, before and after a priming phosphorylation, were not investigated for most of these substrates. Phosphorylation of cyclin B by Erk, however, was found to dramatically enhance its subsequent phosphorylation by Plk1 (Yuan et al., 2002) , suggesting a potential role of PBD binding in cyclin B phosphorylation by Plk1. Another protein, Emi1, was recently identified as a Plk1 substrate in vitro (Moshe et al., 2004) . Emi1 could be phosphorylated by nonphysiological concentrations of Plk1 that were B20-fold higher than those found in mitotic extracts. However, if Emi1 was first phosphorylated by Cdk1, then the amount of Plk1 that was required was reduced to physiological levels. Quantification of this effect revealed that incubation of Emi1 with Cdk1 prior to incubation with Plk1 increased the phosphorylation of Emi1 by Plk1 by threefold (Moshe et al., 2004) . Unfortunately the sites of Cdk1 phosphorylation on Emi1 or the ability of Emi1 to associate with the PBD of Plk1 were not examined. Nevertheless, this data clearly agrees with a processive phosphorylation model. Another recent study demonstrated that Wee1 phosphorylation by Plk1 was stimulated by phosphorylation of Wee1 by Cdk1 (Watanabe et al., 2004) . The site of phosphorylation by Cdk1 perfectly matched a consensus site for PBD binding again indicating a role for the processive model though this interaction was not directly addressed in the study. A separate study demonstrated that these same events likely occur for the budding yeast homolog of Wee1 and Swe1, although the priming kinase was suggested to be Cla4 instead of Cdk1 (Sakchaisri et al., 2004) .
Very recently a novel substrate of Plx1, claspin, was described (Kumagai and Dunphy, 2000) . Claspin binds to the PBD of Plx1 through a phospho-dependent interaction and is subsequently phosphorylated on a nearby site (Yoo et al., 2004) . The timing of these two events was clearly delineated, and the necessity of PBD binding for the subsequent phosphorylation event was demonstrated. Thus, claspin is the first Plk substrate to definitively use the processive phosphorylation model, although cyclin B, Emi1, and Wee1 are very strong candidates for additional Plk substrates that use this process. A second alternative model is the 'distributive phosphorylation' model in which the ligand to which the PBD binds is distinct from the substrates which the Plk kinase domain phosphorylates (Figure 3 ). In this case, PBD-binding to a phosphorylated scaffold or docking protein localizes the kinase domain to specific subcellular structures, vicinal to substrates of the kinase domain that could even be bound to the same scaffold molecule. The movement of Plk1 from centrosomes to kinetochores and the spindle midzone, and then to the septin ring as cells progress from G 2 through mitosis is consistent with this model. Most of the putative scaffold molecules are yet to be defined, but there are at least two potential examples of such Plk1 scaffolds. One of the roles of Plk1-related family members is the activation of the anaphase promoting complex (APC), and Cdc23/ Cut23 is responsible for localizing Plk/Plo1 to the APC, where additional Plk1/Plo1 substrates are found (Golan et al., 2002; May et al., 2002) . The kinesin-like proteins Mklp1/2, which seem to carry Plk1 to the central spindle during anaphase and telophase (Neef et al., 2003; Liu et al., 2004) , may be the scaffolds for Plk1's role in cytokinesis, which presumably requires multiple substrates. Both of the Plk1 scaffolds, Cut23 and Mklp1/2, are themselves substrates of Plk1, suggesting that they function as more than simple docking sites.
Both models will surely turn out to be correct for specific Plk substrates, although which model will predominate is an open question. In either case, the PBD appears to function as an 'AND' gate in the lingo of systems biology, by 'integrating' the activity of other mitotic kinases with that of Plks. By functioning as a pSer/pThr-binding module, the PBD ensures that Plkmediated progression through M phase and sequential activation of discrete mitotic events occurs if, and only if, a prior CDK/MAPK or other mitotic kinase phosphorylation has occurred. In the processive phosphorylation model, the PBD functions as an 'integrator' in time -the priming phosphorylation event has to occur at the same time that Plk kinase is present and active, or else the PBD-binding site will be lost through the rapid action of phosphatases. In the distributive phosphorylation model, the PBD functions as an 'integrator' in space -substrates must be localized in close proximity to the phosphorylated scaffold molecule to which the PBD has bound.
Activation and phosphorylation of Plks
The cell cycle dynamics of Plks has been examined primarily for Cdc5 and Plk1. The levels of these Plks rise dramatically in the G 2 phase of the cell cycle starting from undetectable levels during G 1 and beginning their rise in mid S phase (Golsteyn et al., 1994; Hardy and Pautz, 1996; Cheng et al., 1998) . With this rise in protein levels there is a concordant increase in kinase activity, but the activity rises much more dramatically than the levels, implicating an activation event (Golsteyn et al., 1995; Hamanaka et al., 1995; Cheng et al., 1998) . Both the protein levels and the activity peak at the metaphase-anaphase transition before returning to the interphase baseline at the beginning of the next G 1 phase due to degradation of these Plks by the APC/C (Hamanaka et al., 1995; Charles et al., 1998; Cheng et al., 1998; Shirayama et al., 1998; Lindon and Pines, 2004) .
Studies of Plk1, Plx1, Polo, and Cdc5 have established that activation of these kinases requires their direct phosphorylation (Hamanaka et al., 1995; Tavares et al., 1996; Mundt et al., 1997; Cheng et al., 1998; Qian et al., 1998b) . Plk1 and Plx1 activation have been the most extensively examined in mechanistic and structural detail, although activation of other family members is believed to occur through the same mechanisms. Several conserved Ser and Thr residues are present within the kinase domains of Plks. Mutation of two of these, T210 and S137 in Plk1 (or the corresponding residues T201 and S128 in Plx1), to Asp as a mimic of phosphorylation results in the formation of activated Plk1 and Plx1 (Lee and Erikson, 1997; Qian et al., 1999; Jang et al., 2002b) . Mutation of these residues results in multiple mitotic phenotypes as discussed below.
T210/201 lies within the T-loop of the Plk kinase domain, and has been confirmed to be an in vivo phosphorylation site through phosphopeptide mapping of Plk1 immunoprecipitated from nocodazole-arrested lysates and Plx1 immunoprecipitated from mitotic Xenopus egg extracts (Jang et al., 2002b; Kelm et al., 2002) . Phosphorylation in T loops is a common mechanism of activation for many protein kinases including Aurora A/B, PKA, Cdk1/2, Erk1/2, Rsk1/2, Akt/PKB, and Mek1 (Johnson et al., 1996) . Unfortunately, the lack of a phospho-specific antibody against the Plk1 T210/201 site has prevented detailed studies correlating phosphorylation at this site with the activity of Plks or specific phenotypes. Still it is generally believed that phosphorylation at T210 is a requirement for Plk activation because the phosphomimic mutations mentioned earlier activate the kinase, and T210-V mutations prevent activation (Lee and Erikson, 1997; Qian et al., 1999; Jang et al., 2002b) . The corresponding phosphomimic mutation in human Plk2 also activates the kinase (Ma et al., 2003) , suggesting that this is a conserved mechanism of Plk activation.
Production of a T201-D mutant form of Plx1 in a Xenopus egg extract system resulted in acceleration of Cdc25C activation during mitotic entry and delayed Cdc25C deactivation during mitotic exit, although T201D expression was not sufficient to induce the first mitotic cell cycle. Additionally, there was a delay in cyclin B2 degradation during anaphase and a corresponding delay in the loss of Cdc2 kinase activity (Qian et al., 1999) . On the other hand, overexpression of a T210-D mutant form of Plk1 in HeLa cells caused an increased G 2 /M population, but only slighty more so than overexpression of wild-type Plk1 or even kinasedead Plk1 (Jang et al., 2002b) . At later times, overexpression of wild-type or kinase-dead Plk1 delayed mitotic exit, leading these cells to ultimately exit mitosis without undergoing cytokinesis (Mundt et al., 1997) .
There have been at least two proposals for the upstream kinase that phosphorylates T210/201 -Xeno-pus Plkk1 (equivalent to human SLK or Stk10) and PKA. xPlkk1 was purified as the Plx1 T201 phosphorylating factor in Xenopus oocyte extracts (Qian et al., 1998b) . A recent study demonstrated that xPlkk1 may actually be downstream of Plx1 and the two kinases could function in a positive feedback loop . Immunodepletion of xPlkk1 did not prevent activation of Plx1 or alter the kinetics of mitotic entry in Xenopus egg extracts as monitored by H1 kinase activity, implying that this loop is not required. Activation of Plx1 by phosphorylation was still required, implying that there must be another kinase that can phosphorylate Plx1 T201 in the xPlkk1-depleted extracts. Both human SLK and Stk10 have been shown to phosphorylate human Plk1 at T210 in vitro and are able to stimulate Plk1 activation in vivo (Ellinger-Ziegelbauer et al., 2000; Walter et al., 2003) . It was previously believed that Stk10 could not be the Plk1-activating kinase because the mouse homolog, LOK, was only expressed in lymphatic tissues. However, more complete expression profiling has shown that Stk10 is expressed in most tissues, so both SLK and Stk10 remain viable candidates or partners for Plk1 T210 phosphorylation. PKA has also been shown to be able to phosphorylate T201 and activate Plx1 activity in vitro . In this same study, xPlkk1 was not able to phosphorylate Plx1 T201 creating a currently unresolved discrepancy in the field.
In contrast to T210/201, there is no direct evidence for the in vivo phosphorylation of S137/128. At least two studies searched directly for S137/128 phosphorylation using tryptic phosphopeptide analysis combined with mass-spectrometry in mitotic Xenopus extracts , and phosphopeptide mapping and phosphoamino acid analysis in mammalian cells (Jang et al., 2002b) , and both came up short. Although these and other studies did identify a number of other phosphoserine residues (Hamanaka et al., 1995; Qian et al., 1998b; Kelm et al., 2002; Wind et al., 2002) , none of these sites has been shown to have functional significance. Furthermore, mutation of S137-A failed to prevent activation of Plk1/Plx1 and did not produce any noticeable phenotypes when overexpressed, suggesting that phosphorylation of this site is not critical in vivo (Qian et al., 1999; Jang et al., 2002b) . Still the phenotypes seen with an S137-D mutant form of Plk1 are striking. When overexpressed in HeLa cells, the S137D mutant Plk1 caused the cells to arrest as a G 1 /S population rather than the G 2 /M population seen with T210D or wild type, and the double mutant S137D/ T210D also shows the G 1 /S block (Jang et al., 2002b) . The equivalent S128D/T201D double mutant in Plx1 caused cleavage arrest resulting in large cells when injected into a Xenopus two cell embryo, and was able to induce the first mitotic cycle in a Xenopus egg extract system unlike wild-type or single mutants of Plx1 (Qian et al., 1999) . Together, these data suggest that if S137/ 128 is phosphorylated in vivo, it is probably only a transient event during late mitosis.
The systems that have been used to map phosphorylation sites in Plks have focused primarily on metaphase-arrested or asynchronous cells, and were therefore better suited to identify stable phosphorylation sites, perhaps explaining the failure to observe Ser-137/128 phosphorylation to date. Since Plks show striking changes in subcellular localization during anaphase and telophase, and participate in different processes at these times than during earlier stages of mitosis (Barr et al., 2004) , the possibility for additional post-translational modifications of Plks, such as Ser-137 phosphorylation, during the postmetaphase stages remains promising. Demonstration that Ser-137/128 is phosphorylated in vivo, and identifying an upstream kinase responsible for this event, would constitute a seminal advance in the field.
Structure of the Sak Polo-box
Structural analysis of the Polo-box first emerged from the crystal structure of the single Polo-box of murine Sak (residues 845-919) (Leung et al., 2002) . The structure revealed that the Polo-box had crystallized as an intermolecular dimer with a clam-like fold, consisting, in total, of two a-helices and two six-stranded antiparallel b-sheets (Figure 4a ). Each b-sheet contained four contiguous strands from one Polo-box (b-strands 6, 1, 2, and 3), with the remaining two strands coming from the other Polo-box. The association of b-strand 3 from both Polo-boxes formed a hinge region, opposite to which was an interfacial cleft and pocket (B17 Â 8 Â 12 Å ). The presence of nine of 19 conserved hydrophobic residues lining the interior of the pocket hinted at a possible ligand-binding function, although actual ligands of the Sak Polo-box dimer remain to be identified.
The dimeric structure of the Sak Polo-box seen in the crystals was also shown to occur within cells using coimmunoprecipitation assays of differentially tagged Sak Polo-box constructs (Leung et al., 2002) . Interestingly, a C-terminal construct of Sak containing residues 596-836 (Sak 241 ) but lacking the Polo-box region was also observed to dimerize, indicating the presence of one or more dimerization domains in addition to the Polobox within Sak. The subcellular localization of enhanced green fluorescence protein (EGFP) fusion constructs of the Polo-box region alone and of full-length Sak in NIH 3T3 cells suggested that the Polo-box may play a role in targeting Sak to centrosomes and the cleavage furrow. However, in contrast to loss of localization observed for Polo-box truncations in other members of the Plk family, subcellular localization of Sak was not disrupted by deletion of the Polo-box. Significant loss of proper subcellular localization of Sak was only observed if both the C-terminal region following the kinase domain but preceeding the Polo-box (residues 596-836) and the Polo-box itself were deleted. Given the ability of the Polo-box and Sak 241 constructs to dimerize, it is unclear if the observed subcellular localizations of these domains result from their interaction with components of centrosomes and the cleavage furrow or from association with endogenous Sak.
Structure of the Plk1 PBD
Crystal structures of the PBD of human Plk1 (Cheng et al., 2003; Elia et al., 2003b) revealed some similarities and a number of key differences with the structure of the Sak Polo-box dimer. Each of the individual Polo-box repeats (PB1 and PB2) in Plk1 consisted of a selfcontained six-stranded b-sheet and a-helix (Figure 4b ). This was similar to the structure of the single a-helix/bsheets seen in the Sak Polo-box dimer, however in the Sak structure, each of the b-sheets contains contributions from two Polo-boxes. In contrast, no strand swapping was observed in the Plk1 PBD b-sandwich. Furthermore, the association between the Polo-box repeats in Plk1 differed completely from that of the Sak Polo-box dimer. The b-sheets in the Plk1 PBD pack together with the two a-helices on either side of the b-sandwich, such that residues located at the interface in the Sak Polo-box homodimer correspond to residues on the exterior faces of the b-sandwich in the Plk1 PBD. The PBD also contained a Polo cap (Pc) region consisting of an a-helix connected via a linker (L1) to the first b-strand of PB1 and a second linker (L2) connecting the two Polo-box repeats, helping to hold both Polo-boxes in the correct orientation.
Peptide library screening to determine the optimal phosphopeptide motifs recognized by the PBDs of human Plk1, Plk2 and Plk3, Xenopus Plx1, and Saccharomyces cerevisiae Cdc5p revealed a strong selection for Ser in the pThr/pSer-1 position and a modest preference for Pro in the pThr/pSer þ 1 position (Elia et al., 2003a; Elia et al., 2003b) . Crystal structures of the human Plk1 PBD in complex with its optimal phosphopeptide revealed the structural basis of the phospho-dependent binding and motif recognition. The phosphopeptide-binding site is located at one end of a shallow cleft between the two b-sheets within the only highly conserved region on the PBD surface. The phosphate group is bound via eight hydrogen-bonding interactions involving indirect contacts through a lattice of ordered water molecules and direct contacts arising from the pincer-like arrangement of the His-538 and Lys-540 side chains. The importance of His-538 and Lys-540 in phosphospecific binding was confirmed by mutation of these residues to Ala, which eliminated binding (Elia et al., 2003b) . The strong selection for Ser at the pThr-1 position can be accounted for by three hydrogen bond interactions of the Ser-1 side chain hydroxyl to the main chain atoms of Trp-414 and with the backbone carbonyl of Leu 491 via a water molecule. Van der Waals contacts between the Ser-1 Cb atom and the Cd1 of a strictly conserved Trp-414 side chain reveal that larger hydroxyl-containing side chains such as Thr or Tyr at the pThr/pSer-1 position would result in a steric clash. The pThr/pSer þ 1 Pro residue makes a smaller contribution to the binding surface and likely increases binding affinity by introducing a kink via its trans peptide conformation to direct the residues Cterminal to it back towards the binding surface, thereby reducing the entropic penalty of binding.
A mutually inhibitory interaction between the Plk1 kinase domain and PBD results in both a B3-fold reduction in kinase activity and a B10-fold reduction in phosphopeptide binding by the PBD with significantly reduced phosphospecificity (Lee and Erikson, 1997; Mundt et al., 1997; Jang et al., 2002a; Elia et al., 2003b) . Conversely, binding of the optimal phosphopeptide to full-length Plk1 stimulated kinase activity by B2.6-fold and suggests that binding of the PBD to substrates with primed phosphorylation sites simultaneously targets Plk1 to its substrates and activates the kinase domain. The structural basis for regulatory interaction between the kinase and PBD remains unclear. In the Src family of protein tyrosine kinases, intramolecular binding of the SH2 domain to a Cterminal phosphotyrosine motif positions the N-terminal SH3 domain for binding to a linker connecting the SH2 and kinase domains (Sicheri et al., 1997; Xu et al., 1999) . The SH3 domain and the linker interact with the (Kraulis, 1991) and Raster3D (Merritt and Murphy, 1994) Structure and function of Polo-like kinases DM Lowery et al kinase domain to stabilize it in an inactive conformation. This mechanism of intramolecular regulation does not appear to be applicable to Plk1, due to the absence of an internal optimal PBD motif. Additionally, mutations of the His-538/Lys-540 pincer residues, which disrupt phosphospecific binding by the PBD, do not abrograte binding of the PBD to the isolated kinase domain in trans. These observations indicate that the sites of interaction on the PBD with phosphopeptide ligands and with the kinase domain are distinct. Partial overlap of these sites, such that binding at one site sterically occludes binding to the other site, however, would provide one possible mechanism of the mutually inhibitory interaction. An alternative mechanism to regulate catalytic activity via an intramolecular phosphopeptide binding domain is illustrated by the SHP family of phosphatases, in which binding of the N-terminal SH2 domain to the phosphatase domain partially occludes the catalytic cleft and distorts the conformation of the SH2 domain, reducing its phospholigand affinity (Hof et al., 1998) . Conversely, phospholigand binding to the SH2 domain results in activation by stabilizing an alternate conformation of the SH2 domain with reduced affinity for the phosphatase domain. A similar 'molecular switch' mechanism may be applicable to the PBD domain and would be consistent with its reduced phosphodependent binding in full-length Plk1 and the increased activity of full-length Plk1 upon addition of optimal phosphopeptide. Crystal structures of the PBD in the apo state and in complex with its optimal phosphopeptide reveal that phosphopeptide binding does not induce significant conformational changes in the PBD (Cheng et al., 2003) . However, a conformational change in the PBD with distortion of its phosphopeptide-binding site upon binding to the kinase domain remains possible. Additionally, it is not known if the kinase active site is simply occluded as in the SHP phosphatases, or if the kinase domain adopts a distinct inactive conformation when bound to the PBD. A crystal structure of full-length Plk1 or a complex of the isolated kinase domain with the PBD will be needed to observe the kinase domain and the PBD in their mutually inhibited states.
Model of the Plk kinase domain
No crystal structure is currently available for a Plk family kinase domain; however, given the high structural conservation of the protein kinase catalytic core in the active conformation, molecular models of kinase domains based on available crystal structures can be used to predict structural features of the active site that may be important for regulation and substrate selectivity. The kinase domain of human Plk1 was therefore modelled using the SWISS-MODEL server (Guex and Peitsch, 1997) based on the crystal structures of Aurora-A (Bayliss et al., 2003) (PDB codes 1Ol5 and 1Ol7), (Nowakowski et al., 2002) (PDB code 1MQ4), Aurora-B (Cheetham et al., 2002) (PDB code 1MUO), and Akt/ PKB (Yang et al., 2002 ) (PDB code 1O6K) ( Figure   5a , b). This Plk1 model was subsequently used as a template to model the Plk2, Plk3, and Plk4 kinase domains (Figure 5c-e) .
Thr-210 of Plk1 is located within the activation segment, a centrally located loop that contributes a significant portion of the peptide substrate-binding site. Similar to other kinases, phosphorylation of T210 in Figure 5 Molecular modelling of the Plk kinase domain. (a) A ribbon figure of a model of the Plk1 kinase domain (residues 48-309) is shown in two orthogonal views and with the N-and Cterminal lobes colored green and blue, respectively. The model of the core kinase domain is based primarily on the structures of Aurora-A and -B (Bayliss et al., 2003; Cheetham et al., 2002; Nowakowski et al., 2002) . The activation loop was modelled in an active conformation using the structure of the Akt/PKB : AMP-PNP : GSK3-peptide ternary complex (Yang et al., 2002) . ATP and a substrate peptide (Gly-Ala-Ala-Ala-Glu-Ala-Ser-Phe-Ala-Ala) are shown in stick representation and were also modelled based on the Akt/PKB : AMP-PNP : GSK3-peptide ternary complex structure (Yang et al., 2002) . The side chains of Ser-137 and phosphorylated are shown in stick representation and highlighted with transparent spheres. Figure created with Molscript (Kraulis, 1991) and Raster3D (Merritt and Murphy, 1994) . Plk1 and its mutation to Asp has a stimulatory effect on kinase activity, as discussed earlier. Phosphorylation of the equivalent Thr in PKA stabilizes the activation loop in an open and extended conformation to allow substrate binding (Knighton et al., 1991a, b) . Additionally, interactions of the phospho-threonine with an adjacent cluster of positively charged side chains and backbone nitrogens may play a role in aligning the N-and C-lobes of the kinase domain into a catalytically competent conformation or in properly orienting and positioning key catalytic residues (Johnson et al., 1996) .
A comparison of the active sites of the four human Plk kinase models suggests that Plk1, Plk2, and Plk3 may share a similar substrate phosphorylation motif, while the sequence motif phosphorylated by Plk4 may differ significantly. Based on the phosphorylation sites of known substrates and mutational studies, a consensus recognition motif for Plk1 has been deduced and consists of Glu/Asp at the À2 position and a hydrophobic residue in the þ 1 position relative to the phosphorylated Ser/Thr residue (Toyoshima-Morimoto et al., 2001; Toyoshima-Morimoto et al., 2002; Casenghi et al., 2003; Jackman et al., 2003; Lin et al., 2003; Nakajima et al., 2003; Neef et al., 2003) . A peptide corresponding to this motif was therefore modelled into the active site using the crystal structure of Akt/PKB in complex with GSK3-peptide and AMP-PNP (Yang et al., 2002) . The distibution of electrostatic potential within the modelled Plk1 active site is consistent with this putative substrate phosphorylation motif. A hydrophobic pocket at the þ 1 position appears to be conserved in all four kinase domains, while a positively charged region lies in close proximity to the substrate Ser/Thr-2 position in Plk1, Plk2, and Plk3 but not in Plk4. In Plk4, Thr-138 substitutes for a Lys residue, which is conserved in the other three Plks at this position (Lys 178 in Plk1).
Ser-137 of Plk1 shares a similar surrounding sequence context as Thr-210 and has been proposed to be a second site of phosphorylation (Jang et al., 2002b) , although this remains controversial as discussed above. In the Plk1 kinase model, Ser-137 is solvent exposed and located within the peptide-binding cleft near the predicted substrate Ser/Thr-3 position. Phosphorylation of Ser-137 would be expected to introduce a strong negative charge and increase selectivity for a positively charged residue such as Arg or Lys in the substrate at the À3 position. Interestingly, the crystal structure of Akt/PKB in complex with GSK3-peptide shows a negatively charged residue at this position (Glu 236) forming a bidentate salt bridge to the À3 Arg of GSK3-peptide (Yang et al., 2002) . A similar interaction is also observed in the structure of a PKA-peptide complex (Bossemeyer et al., 1993) . Thus, phosphorylation of Ser-137, if it occurs, might be expected to alter Plk substrate specifity, leading to phosphorylation of alternative targets than those selected when Ser-137 is not phosphorylated. Intriguingly, Ser-137 of Plk1 is conserved in Plk2 (Ser 166) and Plk3 (Ser 107) but is replaced with glutamate in Plk4 (Glu 96).
Prospects for structure-based drug design
Plk1 is highly expressed in proliferating cells and in various human tumors including squamous cell cancers of the head and neck, melanomas, gliomas, esophageal, colorectal and lung carcinomas, and endometrial, ovarian and breast cancers (Holtrich et al., 1994; Wolf et al., 1997 Wolf et al., , 2000 Knecht et al., 1999; Tokumitsu et al., 1999; Dietzmann et al., 2001; Takai et al., 2001; Kneisel et al., 2002; Takahashi et al., 2003) . High levels of Plk1 expression in tumors often correlate with poor prognosis. Constitutive expression of Plk1 in NIH 3T3 cells causes malignant transformation and induces tumor growth in nude mice (Smith et al., 1997) . Importantly, antisense oligonucleotides that downregulate Plk1 cause decreased cell proliferation in MDA-MB-435 breast cancer cells and A549 non-small-cell lung cancer cells in vitro and in tumor regression when these cells were xenografted onto nude mice (Spankuch-Schmitt et al., 2002; Elez et al., 2003) . Interestingly, the viability of nontransformed cells such as amniocytes, mesangial cells, and skin fibroblasts was unaffected by these types of Plk1 downregulation (Elez et al., 2003) . These observations strongly indicate that Plk1 is likely to be a highly effective target for anticancer drug design.
The Plk1 kinase domain is an obvious target for drug development, and high-throughput screening and structure-based approaches used in the discovery and optimization of inhibitors of other protein kinases can be applied (Fabbro et al., 2002; Noble et al., 2004; Stout et al., 2004) . The deep cavity of the ATP-binding pocket of kinases provides an excellent binding site for small molecules, and consequently the majority of available kinase inhibitors are ATP analogs. The lack of specificity of many such inhibitors is a significant problem, however, owing to the highly conserved nature of the ATP-binding pocket. In some cases, selectivity can be achieved by exploiting unique structural features. For example, deschloro-flavopiridol utilizes an additional less-conserved pocket within the ATP-binding site of CDK2 (De Azevedo et al., 1996) . The diaryl urea, and quinazolinone and pyridol-pyrimidine classes of p38 MAP kinase inhibitors also exploit novel binding sites within the ATP-binding pocket, some of which are created by inducing subtle conformational changes (Tong et al., 1997; Pargellis et al., 2002; Fitzgerald et al., 2003) . High specificity is also achieved by targeting a distinct inactive conformation of a kinase as shown by the inhibition of Abelson tyrosine kinase by STI571/Gleevec (Schindler et al., 2000) . Important to the development of Plk1 inhibitors that target the kinase domain will be the ability to produce sufficient quantities of either the full-length Plk1 or kinase domain for high-throughput screening and crystallographic studies. Crystal structures of the Plk1 kinase domain in both the active and inactive conformations will be extremely valuable for the optimization of lead compounds.
The PBD presents an additional unique target for the development of novel and specific Plk inhibitors, since it is essential for normal Plk function. To date, disruption of protein-protein interactions have been looked upon unfavorably as targets for drug design, primarily because such interactions often involve burial of large amounts of hydrophobic surface. However, the identification of a relatively polar, small optimal phosphopeptide ligand for the PBD capable of disrupting Plksubstrate interactions (Elia et al., 2003a) suggests that small molecules should be sufficient to accomplish this task. Furthermore, the availability of Plk PBD optimal phosphopeptides should facilitate development of high throughput assays for small molecule inhibitors that will disrupt PBD function, while the availability of crystal structures of the PBD-phosphopeptide complex will facilitate structure-based optimization of any lead compounds identified in these screens.
